Study summary
Finerenone cut worsening heart failure in people with preserved pumping
842worsening heart failure events with finerenone, vs 1,024 with placebo
What was tested
Finerenone, a non-steroid mineralocorticoid receptor antagonist pill, against placebo in heart failure with an ejection fraction of 40% or more (mildly reduced or preserved).
What they found
- Total worsening heart failure events were 842 vs 1,024.
- Cardiovascular deaths were similar (8.1% vs 8.7%).
- High potassium was more common.
What it means
Gives HFpEF and HFmrEF a second proven drug class after SGLT2 inhibitors.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.